Jupiteur biotechnology also conducts its own technology development research. The company seeks to develop point-of-care (POC) multiplex diagnostic technologies using miniature platforms that can support over 3000 separate diagnostic tests simultaneously, on a 2 x 6 cm surface. Currently Jupiteur biotechnology is working on the multiplexing of HIV and TB diagnostic tests for applications at POC or near patients. This will contribute in improving the management of HIV and M.tb co-infections, especially for people living in rural or remote areas. However, Jupiteur biotechnology does not intend to stop here but to multiplex the tests of many other communicable or non-communicable diseases, also for applications at POC or near patients. Although our current research is on qualitative tests i.e. intended to answer the question of whether a disease is present or not; in the near future Jupiteur biotechnology R&D will involve the detection, still on a miniaturized platform, of biomarkers that will assist with treatment outcome and/or disease progression monitoring.